Vantage Urologic Institute

About Us


Excellence in Urologic Healthcare

The Vantage Urologic Institue is rapidly establishing a reputation for urologic innovation and excellence in patient centered care.  Founded by D. Russell Locke, M.D., the Institute delivers world-class urologic care and is consistently recognized as one of the region's top community-based urology programs.

The Institute is a leader in minimally invasive and robot-assisted surgery for cancer and disease of the genitourinary system.  Dr. Locke and his surgical team were among the first to embrace minimally invasive technology, including robotics, and to actively introduce them into clinical practice.

The Vantage Urologic Institute is recognized as a leader in translational genomics.  Translational genomic research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer and other complex diseases.  Our physician scientists "translates" (or applies) observations from molecular genetics research studies to clinical practice bridging the gap between lab bench discoveries and the patient bedside. Under the leadership or our physicians and researchers, we continually endeavor to make leading-edge advances in genomic medicine that will impact patient care.